These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 3931665)

  • 1. Leuprolide: a review of its effects in comparison with diethylstilboestrol in the treatment of advanced cancer of the prostate.
    Garnick MB; Glode LM; Smith JA; Max DT
    Br J Clin Pract Suppl; 1985 Mar; 37():8-12, 20-4. PubMed ID: 3931665
    [No Abstract]   [Full Text] [Related]  

  • 2. Leuprolide: a review of its effects in comparison with diethylstilboestrol in the treatment of advanced cancer of the prostate.
    Garnick MB; Glode LM; Smith JA; Max DT
    Br J Clin Pract; 1985 Feb; 39(2):73-6. PubMed ID: 3921047
    [No Abstract]   [Full Text] [Related]  

  • 3. Leuprolide versus diethylstilbestrol for previously untreated stage D2 prostate cancer. Results of a prospectively randomized trial.
    Garnick MB
    Urology; 1986 Jan; 27(1 Suppl):21-8. PubMed ID: 3079935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III studies in prostatic cancer with leuprolide acetate.
    Seely JH
    J Androl; 1987; 8(1):S23-6. PubMed ID: 3104263
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of leuprolide and diethylstilbestrol for stage D2 adenocarcinoma of prostate.
    Sharifi R; Lee M; Ojeda L; Ray P; Stobnicki M; Guinan P
    Urology; 1985 Aug; 26(2):117-24. PubMed ID: 3927551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leuprolide versus diethylstilbestrol for metastatic prostate cancer.
    Leuprolide Study Group
    N Engl J Med; 1984 Nov; 311(20):1281-6. PubMed ID: 6436700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of prostatic cancer with slow-release formulation of luteinizing hormone releasing hormone (LH-RH) analog].
    Fuse H; Akimoto S; Akakura K; Shimazaki J; Murakami S
    Hinyokika Kiyo; 1988 Mar; 34(3):555-60. PubMed ID: 3133936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study of a long acting luteinizing hormone releasing hormone agonist (Decapeptyl) and orchiectomy in the treatment of advanced prostatic cancer. Preliminary report.
    De Sy WA; de Meyer JM; Casselman J; De Smet R; Renders G; Schelfhout W; De Wilde P
    Acta Urol Belg; 1986; 54(2):221-9. PubMed ID: 2942015
    [No Abstract]   [Full Text] [Related]  

  • 9. Hormonal therapy for prostate cancer.
    Torti FM
    N Engl J Med; 1984 Nov; 311(20):1313-4. PubMed ID: 6436701
    [No Abstract]   [Full Text] [Related]  

  • 10. LHRH analogues in the treatment of prostatic cancer. Introduction.
    Dufour B
    Br J Clin Pract Suppl; 1985 Mar; 37():2-3, 14-5. PubMed ID: 3931663
    [No Abstract]   [Full Text] [Related]  

  • 11. Leuprolide: a review of its effects in animals and man.
    Drago JR; Rohner T; Santen R; Manni A; Lipton A; Harvey H; English H
    Br J Clin Pract Suppl; 1985 Mar; 37():4-7, 16-9. PubMed ID: 3931664
    [No Abstract]   [Full Text] [Related]  

  • 12. Leuprolide for prostate cancer.
    Med Lett Drugs Ther; 1985 Aug; 27(694):71-2. PubMed ID: 2410765
    [No Abstract]   [Full Text] [Related]  

  • 13. Analysis of testosterone suppression in men receiving histrelin, a novel GnRH agonist for the treatment of prostate cancer.
    Djavan B; Schlegel P; Salomon G; Eckersberger E; Sadri H; Graefen M
    Can J Urol; 2010 Aug; 17(4):5265-71. PubMed ID: 20735905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leuprolide: a gonadotropin-releasing hormone analog for the palliative treatment of prostatic cancer.
    Wojciechowski NJ; Carter CA; Skoutakis VA; Bess DT; Falbe WJ; Mickle TR
    Drug Intell Clin Pharm; 1986 Oct; 20(10):746-51. PubMed ID: 2429815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of metastatic carcinoma of the prostate with leuprolide, an LHRH analogue.
    Smith JA
    Prog Clin Biol Res; 1985; 185A():279-85. PubMed ID: 3929267
    [No Abstract]   [Full Text] [Related]  

  • 16. Luteinizing hormone-releasing hormone (LH-RH) analogs in treatment of prostatic cancer. Clinical perspective.
    Smith JA
    Urology; 1986 Jan; 27(1 Suppl):9-15. PubMed ID: 3079936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy over time of LHRH analogs in the treatment of PCa--a prospective analysis using serum testosterone to determine dosing intervals.
    Greil S; Robinson EA; Singal B; Kleer E
    Urology; 2009 Mar; 73(3):631-4. PubMed ID: 19110301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The treatment of prostatic cancer by LH-RH agonist.
    Imai K; Yamanaka H; Yuasa H; Yoshida M; Asano M; Kaetsu I
    Prog Clin Biol Res; 1987; 243A():429-34. PubMed ID: 3116552
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate.
    Smith JA; Glode LM; Wettlaufer JN; Stein BS; Glass AG; Max DT; Anbar D; Jagst CL; Murphy GP
    Urology; 1985 Feb; 25(2):106-14. PubMed ID: 3918369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leuprolide: a review of its effects in animals and man.
    Drago JR; Rohner T; Santen R; Manni A; English H; Lipton A; Harvey H
    Br J Clin Pract; 1985 Feb; 39(2):77-9. PubMed ID: 3921048
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.